Results 71 to 80 of about 1,009 (151)

A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients

Therapeutic Advances in Hematology
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological cancer. Due to its low incidence, researchers struggle to gather sufficient prospective data to inform clinical treatment.
Chen Gong, Ying Liu, Mingzhi Zhang
doaj   +1 more source

Detection of Hematological Malignancies Using N‐NOSE (Nematode‐NOSE)

Hematological Oncology, Volume 43, Issue 3, May 2025.
ABSTRACT Hematological malignancies often lack defined risk factors and present with non‐specific symptoms, underscoring the urgent need for simple and reliable detection methods. To address this challenge, Hirotsu et al. innovated N‐NOSE, a novel, non‐invasive cancer screening test that utilizes the chemotaxis response of the nematode Caenorhabditis ...
Shingen Nakamura, Hideyuki Hatakeyama, Sumiko Yoshida, Umbhorn Ungkulpasvich, Takaaki Hirotsu, Eric di Luccio, Masahiro Abe   +6 more
wiley   +1 more source

Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients

eJHaem
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) predominantly occurs in adults ≥60 years old; 10–20% of cases are pediatric or adolescent/young adult (AYA) patients.
Naveen Pemmaraju, Branko Cuglievan, Joseph Lasky, Albert Kheradpour, Nobuko Hijiya, Anthony S. Stein, Soheil Meshinchi, Craig A. Mullen, Emanuele Angelucci, Luciana Vinti, Tariq I. Mughal, Anna B. Pawlowska   +11 more
doaj   +1 more source

Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR‐NK Cell Engineering

Cell Proliferation, Volume 58, Issue 4, April 2025.
This manuscript provides a comprehensive overview of the state‐of‐the‐art in non‐viral CAR‐NK cell engineering, highlighting its potential to revolutionise cancer treatment. ABSTRACT The recent advancements in cancer immunotherapy have spotlighted the potential of natural killer (NK) cells, particularly chimeric antigen receptor (CAR)–transduced NK ...
Zhaokai Zhou, Yifeng Chen, Yuhao Ba, Hui Xu, Anning Zuo, Shutong Liu, Yuyuan Zhang, Siyuan Weng, Yuqing Ren, Peng Luo, Quan Cheng, Lulu Zuo, Shanshan Zhu, Xing Zhou, Chuhan Zhang, Yukang Chen, Xinwei Han, Teng Pan, Zaoqu Liu   +18 more
wiley   +1 more source

Blastic Plasmocytoid Dendritic Cell Neoplasm With Pseudo‐Lymphoid Morphology Mimicking Lymphoid Malignancy

American Journal of Hematology, Volume 100, Issue 8, Page 1432-1433, August 2025.
Romain Ravel‐Chapuis, Gérard Buchonnet, Catherine Boutet, Francine Garnache Ottou, Anne Roggy, Florian Renosi, Olivier Matray, Victor Bobée   +7 more
wiley   +1 more source

Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Journal of Scientific Research in Medical and Biological Sciences, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN. This manuscript reviews the current understanding of BPDCN pathophysiology, clinical presentation,
openaire   +1 more source

Bruise-like cutaneous lesions as the early presentation of blastic plasmacytoid dendritic cell neoplasm

Dermatologica Sinica, 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare and highly aggressive hematopoietic malignancy associated with a poor prognosis. It has been recognized to originate from precursors of plasmacytoid dendritic cells and has recently been
Yi-Hsuan Chou, Ruey-Yi Lin, Meng-Sui Lee, Hsiao-Ping Wu, Che-Pin Lin, Chen-Yi Wu   +5 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects

Blood and Lymphatic Cancer: Targets and Therapy, 2017
Amy M Trottier, Sonia Cerquozzi, Carolyn J Owen Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+ CD56+
Trottier AM, Cerquozzi S, Owen CJ
doaj  

Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies

Clinical Hematology International, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of plasmacytoid dendritic cells.
Mohamed A. Kharfan-Dabaja, Naveen Pemmaraju, Mohamad Mohty   +2 more
doaj   +1 more source

A new palliative treatment for blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature

Journal of International Medical Research, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy that derives from plasmacytoid dendritic cells. The cancer is characterized by aggressive development and dismal prognosis, and due to limited prospective study ...
Yunning Yang, Yuanyuan Xu, You Nie, Hongwei Wang, Shan Long, Xiaosong Li   +5 more
doaj   +1 more source